These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1836334)

  • 21. Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis.
    Ylikorkala O; Huttunen K; Järvi J; Viinikka L
    Clin Nephrol; 1982 Aug; 18(2):83-7. PubMed ID: 6754193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of acupuncture on the levels of endothelin, TXB2, and 6-keto-PGF1 alpha in apoplexy patients.
    Zhang S; Ye X; Shan Q; Zhang W; Ye L; Cui Y
    J Tradit Chin Med; 1999 Mar; 19(1):39-43. PubMed ID: 10453582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in platelet aggregation, TXB2 and 6-keto-PGF1 alpha in surgical shock].
    Tian L
    Zhonghua Wai Ke Za Zhi; 1990 Jun; 28(6):339-41, 381. PubMed ID: 2096057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes of neurotransmitter endothelin, thromboxance B2 and 6-keto-prostaglandin F1 alpha in patients with chronic pulmonary heart disease].
    Cheng Y; Li ZK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1244-6. PubMed ID: 20584647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imbalance between plasma levels of thromboxane B2 and 6-keto-prostaglandin F1 alpha during subacute endotoxin-induced hyperdynamic sepsis or multiple organ failure syndrome in sheep.
    Pittet JF; Morel DR
    Circ Shock; 1991 Oct; 35(2):65-77. PubMed ID: 1777948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.
    Takeda A; Toda T; Shinohara S; Mogi Y; Matsui N
    Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of atrial natriuretic peptide, thromboxane and prostaglandin production by androgen in elderly men with coronary heart disease.
    Wu S; Weng X
    Chin Med Sci J; 1993 Dec; 8(4):207-9. PubMed ID: 8032065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of xueling on relating substances of renal hypertension in rats].
    Lu G; Li W; Shen K; Shi S
    Zhongguo Zhong Yao Za Zhi; 1998 Jun; 23(6):369-71, 384. PubMed ID: 11601304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of recombinant human erythropoietin on the plasma levels of vasoactive regulatory peptides in patients on maintenance hemodialysis.
    Hegbrant J; Thysell H; Ekman R
    Int J Artif Organs; 1991 Jul; 14(7):411-6. PubMed ID: 1889894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
    Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
    Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in 6 keto PGF1 alpha and TXB2 in patients with myocardial infarction.
    Madan ZM; Sainani GS
    J Assoc Physicians India; 1994 Feb; 42(2):111-2. PubMed ID: 7860468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
    Besarab A; Golper TA
    ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between thromboxane B2 and 6-keto-prostaglandin F1 alpha in sepsis.
    Nakae H; Endo S; Inada K; Takakuwa T; Kasai T; Yoshida M
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):297-302. PubMed ID: 8008979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin and atrial natriuretic peptide in non-insulin-dependent diabetic versus nondiabetic patients on chronic hemodialysis.
    Schleiffer T; Nagel D; Franz H; Falk M; Valentiner I; Wildburg G; Stark M; Brass H
    Ren Fail; 1994 Nov; 16(6):747-58. PubMed ID: 7899586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin correction of anemia. Dialysis efficiency, waste retention, and chronic dose variables.
    Paganini EP; Abdulhadi MH; Garcia J; Magnusson MO
    ASAIO Trans; 1989; 35(3):513-5. PubMed ID: 2688718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.